Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17256009 | CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | December 2020 | July 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17132852 | PHARMACEUTICAL SOLID PREPARATION COMPRISING BENZAZEPINES AND PRODUCTION METHOD THEREOF | December 2020 | July 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17131418 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS | December 2020 | May 2022 | Allow | 16 | 2 | 1 | Yes | Yes |
| 17117310 | METHODS FOR PREDICTING AND REDUCING THE RISK OF PRETERM BIRTH | December 2020 | April 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17099221 | PHARMACEUTICAL SOLID PREPARATION COMPRISING BENZAZEPINES AND PRODUCTION METHOD THEREOF | November 2020 | June 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17065097 | AMBRISENTAN FOR USE IN THE TREATMENT OF ACUTE RENAL FAILURE | October 2020 | March 2023 | Allow | 29 | 0 | 1 | No | No |
| 17038651 | DIHYDROETORPHINE FOR THE PROVISION OF PAIN RELIEF AND ANAESTHESIA | September 2020 | May 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17001124 | PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATION AND PAIN | August 2020 | March 2023 | Abandon | 31 | 1 | 0 | No | No |
| 16987974 | COMBINATION THERAPIES TARGETING MITOCHONDRIA FOR CANCER THERAPY | August 2020 | March 2024 | Abandon | 43 | 2 | 1 | No | No |
| 16985187 | COMBINATION OF AN ANTIMUSCARINIC OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF | August 2020 | December 2022 | Abandon | 29 | 3 | 1 | Yes | No |
| 16938767 | ANTIVIRAL COMPOUNDS | July 2020 | March 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16964023 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | July 2020 | October 2022 | Abandon | 27 | 0 | 1 | No | No |
| 16933166 | USE OF CCR5 ANTAGONISTS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER | July 2020 | June 2024 | Abandon | 47 | 3 | 0 | Yes | No |
| 16958924 | Methods for Treating Neutrophilic Dermatoses with SYK Inhibitors | June 2020 | March 2024 | Abandon | 45 | 3 | 1 | No | No |
| 16957482 | H2S-BASED THERAPEUTIC AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | June 2020 | September 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16892215 | DELIVERY OF A CHEMOTHERAPY AGENT ACROSS THE BLOOD-BRAIN BARRIER | June 2020 | January 2022 | Allow | 19 | 0 | 0 | No | No |
| 16892103 | LIQUID COMPOSITION COMPRISING MEFENTRIFLUCONAZOLE | June 2020 | February 2022 | Allow | 20 | 3 | 1 | No | No |
| 16876505 | PROCESS FOR THE PREPARATION OF A FREEZE-DRIED PHARMACEUTICAL COMPOSITION CONTAINING MITOMYCIN C | May 2020 | June 2023 | Allow | 36 | 2 | 0 | No | No |
| 16875487 | METHODS OF USING PROBENECID FOR TREATMENT OF CORONAVIRUS INFECTIONS | May 2020 | March 2021 | Allow | 10 | 1 | 1 | Yes | No |
| 16851047 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | April 2020 | April 2023 | Allow | 36 | 4 | 1 | Yes | No |
| 16836893 | THERAPEUTIC COMPOSITIONS OF DECANOIC ACID AND ARGININE | March 2020 | June 2021 | Allow | 14 | 1 | 1 | No | No |
| 16823411 | Dihydrotestosterone and Dihydrotestosterone Derivatives and Promoters in the Treatment of Cancer | March 2020 | June 2023 | Abandon | 39 | 4 | 1 | No | No |
| 16811728 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | March 2020 | August 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16808513 | EZH2 INHIBITORS FOR TREATING LYMPHOMA | March 2020 | February 2023 | Allow | 35 | 1 | 1 | No | No |
| 16804178 | PERIODONTIC TREATMENT AND METHOD | February 2020 | April 2021 | Allow | 14 | 1 | 1 | Yes | No |
| 16803824 | METHODS OF TREATING LIVER DISEASE | February 2020 | July 2023 | Allow | 41 | 2 | 0 | No | No |
| 16802916 | METHODS OF TREATING ORAL MUCOSITIS | February 2020 | November 2022 | Allow | 32 | 1 | 0 | No | No |
| 16798176 | PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE | February 2020 | July 2024 | Abandon | 53 | 6 | 1 | No | Yes |
| 16793581 | TREATMENT FOR DRY EYE | February 2020 | July 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16738351 | EXTREME LOW DOSE THC AS A THERAPEUTIC AND PROPHYLACTIC AGENT FOR ALZHEIMER'S DISEASE | January 2020 | May 2022 | Allow | 28 | 1 | 1 | No | No |
| 16727508 | METHODS OF TREATING MUSCLE CRAMPING AND RELATED COMPOSITIONS | December 2019 | January 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16625006 | METHODS FOR TREATING CANCER | December 2019 | March 2023 | Abandon | 39 | 0 | 1 | No | No |
| 16705277 | Imidazolecarboxamides and Their Use as FAAH Inhibitors | December 2019 | October 2021 | Abandon | 23 | 1 | 1 | No | No |
| 16702939 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | December 2019 | May 2023 | Abandon | 41 | 3 | 1 | No | No |
| 16614785 | DUAL MODULATORS OF FARNESOID X RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE | November 2019 | May 2023 | Abandon | 42 | 2 | 1 | Yes | No |
| 16471760 | COMPOSITION FOR IMPROVEMENT OF SLEEP OR FOR PREVENTION OR TREATMENT OF SLEEP DISORDERS, CONTAINING BETA-LAPACHONE | November 2019 | December 2021 | Allow | 30 | 1 | 0 | No | No |
| 16614356 | METHODS FOR TREATING CYSTIC FIBROSIS | November 2019 | February 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16685632 | PHARMACEUTICAL FORMULATION OF LONAFARNIB WITH A SULFOBUTYLETHER BETA-CYCLODEXTRIN | November 2019 | September 2022 | Abandon | 34 | 2 | 1 | No | No |
| 16685841 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | November 2019 | December 2021 | Allow | 25 | 0 | 1 | No | No |
| 16684644 | ACLY INHIBITORS AND USES THEREOF | November 2019 | June 2022 | Allow | 31 | 2 | 1 | Yes | No |
| 16614268 | N-SUBSTITUTED INDOLE DERIVATIVES | November 2019 | January 2022 | Allow | 27 | 1 | 1 | No | No |
| 16614251 | Antibiotic Compounds | November 2019 | August 2021 | Allow | 21 | 1 | 1 | No | No |
| 16681086 | ANTICANCER COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND A METHOD OF TREATING CANCER | November 2019 | September 2021 | Allow | 22 | 2 | 1 | No | No |
| 16680093 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | November 2019 | February 2021 | Allow | 15 | 1 | 0 | No | No |
| 16675780 | Pharmaceutical Composition Of S-Ketamine Hydrochloride | November 2019 | June 2023 | Abandon | 43 | 2 | 1 | No | No |
| 16675267 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | November 2019 | February 2022 | Allow | 27 | 1 | 0 | No | No |
| 16607611 | Rucaparib, Talazoparib, Veliparib, Olaparib and AZD 2461 for Treating Impaired Skin Wound Healing | October 2019 | December 2022 | Allow | 38 | 4 | 1 | Yes | No |
| 16586136 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | September 2019 | April 2021 | Abandon | 18 | 0 | 1 | No | No |
| 16580883 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | September 2019 | January 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16579054 | THERAPEUTIC FORMULATION FOR REDUCED DRUG SIDE EFFECTS | September 2019 | October 2020 | Allow | 13 | 0 | 0 | No | No |
| 16575213 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS | September 2019 | March 2021 | Abandon | 18 | 0 | 1 | No | No |
| 16552380 | INHIBITION OF MAMMALIAN TARGET OF RAPAMYCIN | August 2019 | April 2021 | Allow | 20 | 1 | 1 | No | No |
| 16486974 | USE OF A FEED COMPOSITION FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | August 2019 | July 2021 | Allow | 23 | 1 | 1 | No | No |
| 16530127 | METHODS OF TREATING CONSTIPATION USING AMINOSTEROL COMPOSITIONS | August 2019 | May 2023 | Abandon | 45 | 4 | 1 | No | No |
| 16530295 | AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION | August 2019 | December 2022 | Abandon | 41 | 3 | 1 | Yes | Yes |
| 16530051 | METHODS OF TREATING ALZHEIMER'S DISEASE USING AMINOSTEROL COMPOSITIONS | August 2019 | December 2022 | Abandon | 41 | 3 | 1 | Yes | No |
| 16530247 | METHODS OF TREATING MULTIPLE SYSTEM ATROPHY USING AMINOSTEROL COMPOSITIONS | August 2019 | December 2022 | Abandon | 41 | 3 | 1 | Yes | Yes |
| 16530200 | METHODS OF TREATING AUTISM SPECTRUM DISORDER USING AMINOSTEROL COMPOSITIONS | August 2019 | May 2023 | Abandon | 46 | 4 | 1 | Yes | No |
| 16460473 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO INCREASED EOSINOPHILS | July 2019 | February 2021 | Allow | 20 | 0 | 1 | No | No |
| 16473771 | APTAMER-DRUG CONJUGATE AND USE THEREOF | June 2019 | June 2022 | Allow | 35 | 1 | 1 | No | No |
| 16442294 | PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED SOLUBILIZER RELEASE | June 2019 | January 2023 | Abandon | 43 | 3 | 1 | Yes | No |
| 16404204 | CANCER DIAGNOSIS, TREATMENT SELECTION AND TREATMENT | May 2019 | January 2021 | Abandon | 21 | 0 | 1 | No | No |
| 16403444 | STABLE ORAL LIQUID COMPOSITIONS OF ENALAPRIL | May 2019 | December 2021 | Abandon | 32 | 2 | 1 | No | No |
| 16399432 | PALYTOXYN, ITS MEDICAL USE AND PROCESS FOR ITS ISOLATION | April 2019 | July 2021 | Abandon | 26 | 1 | 1 | No | No |
| 16398827 | ICOTINIB-CONTAINING TOPICAL SKIN PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | April 2019 | February 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16343854 | USE OF PYRAZIFLUMID FOR CONTROLLING SCLEROTINIA SPP IN SEED TREATMENT APPLICATIONS | April 2019 | February 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16382727 | PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES | April 2019 | August 2021 | Allow | 28 | 4 | 0 | Yes | No |
| 16341770 | FGFR REGULATION FOR THE TREATMENT OF VIRAL INFECTIONS | April 2019 | December 2022 | Abandon | 44 | 0 | 1 | No | No |
| 16378089 | ANTIVIRAL COMPOUNDS | April 2019 | January 2021 | Abandon | 21 | 0 | 1 | No | No |
| 16339746 | APPLICATION OF GSK3 INHIBITOR IN PREPARING A DRUG TO TREAT NIEMANN-PICK DISEASE TYPE C | April 2019 | January 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16363427 | METHODS FOR TREATING CANCER | March 2019 | January 2020 | Abandon | 20 | 1 | 0 | No | No |
| 16361711 | VEGETARIAN COMPOSITION CONTAINING UNSATURATED FATTY ACIDS | March 2019 | June 2020 | Abandon | 15 | 1 | 0 | No | No |
| 16281372 | METHOD OF EXPANDING NK CELL AND COMPOSITION FOR CULTURING | February 2019 | May 2021 | Allow | 27 | 2 | 0 | No | No |
| 16277893 | Method of maintaining oral health in animals | February 2019 | November 2022 | Allow | 45 | 4 | 0 | Yes | Yes |
| 16277936 | METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | February 2019 | July 2021 | Abandon | 29 | 2 | 1 | No | No |
| 16269191 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING ANCA ASSOCIATED VASCULITIDES | February 2019 | March 2021 | Abandon | 25 | 1 | 1 | No | No |
| 16254919 | COMBINATION THERAPIES TARGETING MITOCHONDRIA FOR CANCER THERAPY | January 2019 | September 2020 | Abandon | 19 | 0 | 1 | No | No |
| 16243578 | METHOD FOR TREATING INFLAMMATORY DISORDERS | January 2019 | January 2023 | Abandon | 48 | 4 | 1 | No | Yes |
| 16229654 | Pharmaceutical Compositions and Methods for Stabilizing the Same | December 2018 | June 2023 | Abandon | 54 | 4 | 0 | No | No |
| 16227192 | Compositions And Methods For Killing Insect And Non-Insect Pests | December 2018 | August 2023 | Allow | 55 | 7 | 1 | Yes | No |
| 16225493 | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT | December 2018 | August 2020 | Abandon | 20 | 1 | 0 | No | No |
| 16221950 | PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE | December 2018 | December 2021 | Allow | 36 | 2 | 1 | No | Yes |
| 16219564 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS | December 2018 | October 2020 | Allow | 22 | 1 | 0 | No | No |
| 16215060 | Methods For The Effective Treatment Of Metastatic Cancer | December 2018 | March 2023 | Allow | 51 | 5 | 1 | Yes | No |
| 16306946 | USE OF SIGMA RECEPTOR LIGANDS IN CANCER | December 2018 | October 2021 | Abandon | 35 | 2 | 1 | Yes | No |
| 16306970 | POLYMORPH OF BENZAMIDE COMPOUND AND PREPARATION METHOD AND APPLICATIONS THEREOF | December 2018 | April 2021 | Allow | 29 | 1 | 1 | No | No |
| 16306215 | Compositions and methods for targeting and treating homologous recombination-deficient tumors | November 2018 | October 2023 | Abandon | 59 | 4 | 1 | Yes | No |
| 16204074 | METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS | November 2018 | January 2020 | Abandon | 13 | 2 | 0 | No | Yes |
| 16192518 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISEASES | November 2018 | November 2023 | Abandon | 60 | 6 | 1 | Yes | No |
| 15763932 | METHODS OF TREATING INJURIES OR CONDITIONS RELATED TO CNS EDEMA | November 2018 | February 2022 | Abandon | 47 | 2 | 2 | No | No |
| 16181200 | ANTICANCER AGENTS | November 2018 | March 2023 | Allow | 52 | 6 | 1 | Yes | No |
| 16163055 | ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN | October 2018 | December 2021 | Allow | 38 | 4 | 1 | No | No |
| 16159048 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | October 2018 | May 2023 | Abandon | 55 | 6 | 1 | Yes | Yes |
| 16143471 | COMPOUNDS FOR PROTECTION OF CELLS | September 2018 | January 2021 | Allow | 28 | 2 | 1 | No | No |
| 16136201 | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor | September 2018 | November 2023 | Allow | 60 | 5 | 1 | Yes | No |
| 16084340 | AMBRISENTAN FOR USE IN THE TREATMENT OF ACUTE RENAL FAILURE | September 2018 | September 2020 | Allow | 24 | 1 | 1 | Yes | No |
| 16079623 | ORAL DOSAGE FORM OF BOTH CLOMIPHENE ISOMERS AND METHOD OF USING SAME TO TREAT SECONDARY HYPOGONADISM AND MINIMIZE DRUG SIDE EFFECTS IN MEN | August 2018 | March 2021 | Abandon | 31 | 2 | 1 | No | No |
| 16110621 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | August 2018 | November 2019 | Abandon | 15 | 1 | 0 | No | No |
| 16079473 | PIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS WITH INCREASED THERAPEUTIC ACTIVITY | August 2018 | July 2021 | Allow | 35 | 1 | 1 | No | No |
| 16103200 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURONAL INJURY | August 2018 | December 2023 | Abandon | 60 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SIMMONS, CHRIS E.
With a 10.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SIMMONS, CHRIS E works in Art Unit 1629 and has examined 481 patent applications in our dataset. With an allowance rate of 34.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner SIMMONS, CHRIS E's allowance rate of 34.5% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SIMMONS, CHRIS E receive 2.75 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SIMMONS, CHRIS E is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +16.7% benefit to allowance rate for applications examined by SIMMONS, CHRIS E. This interview benefit is in the 57% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 9.7% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 12.7% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 30.8% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 32% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 50.8% of appeals filed. This is in the 22% percentile among all examiners. Of these withdrawals, 53.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 64.3% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 71% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.4% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.